10 stocks we like better than Mylan When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and …
Shares of Mylan N.V. MYL have gained 7.6% in the last three months, as against the industry’s decline of 3.7%. View photos Mylan’s fourth-quarter results were mixed with the bottom line exceeding expectations but the top line lagging …
Glatopa was developed under a collaboration agreement between MNTA and Sandoz and is produced in the US. …
Stock Performance Snapshot March 05, 2018 - At Monday's closing bell, Mylan's stock climbed 1.39%, ending the trading session at $41.54. Volume traded for the day: 3.80 million shares. Stock performance in the last three-month – up …
Past EpiPen pricing litigation and other issues still keeping the stock price low. Post-announcement, MYL is undervalued, but is not a screaming buy if the price rebounds to pre-announcement levels. If the stock bounces back, we …
Mylan's EpiPen price hikes made it the face of corporate greed last summer. Now, the drug maker is lavishing a top exec with an eye-popping pay package. Despite the EpiPen scandal and a slumping stock price, Mylan (MYL) rewarded …
Lawmakers seethed, parents broke into tears at pharmacy counters, regulators opened investigations, competitors raced to come up with cheaper alternatives, and Mylan’s stock tumbled 29 percent. Further Reading Rage mounts against …